©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. May 6, 2016; 7(2): 227-234
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.227
Published online May 6, 2016. doi: 10.4292/wjgpt.v7.i2.227
Update on management of Barrett's esophagus
Fernando Macías-García, J Enrique Domínguez-Muñoz, Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Fernando Macías-García, J Enrique Domínguez-Muñoz, Foundation for Research in Digestive Diseases (FIENAD), University Hospital of Santiago de Compostela, 15706 Santiago de Compostela, Spain
Author contributions: Macías-García F wrote the paper; Domínguez-Muñoz JE supervision and final approval of the article.
Conflict-of-interest statement: Authors declare no conflict of interests for this article.
Correspondence to: Fernando Macías-García, MD, Department of Gastroenterology and Hepatology, University Hospital of Santiago de Compostela, Choupana s/n, 15706 Santiago de Compostela, Spain. fmacgar@yahoo.es
Telephone: +34-98-1951364 Fax: +34-98-1951365
Received: April 25, 2015
Peer-review started: April 27, 2015
First decision: September 8, 2015
Revised: December 15, 2015
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: May 6, 2016
Processing time: 361 Days and 5.2 Hours
Peer-review started: April 27, 2015
First decision: September 8, 2015
Revised: December 15, 2015
Accepted: February 14, 2016
Article in press: February 16, 2016
Published online: May 6, 2016
Processing time: 361 Days and 5.2 Hours
Core Tip
Core tip: Barrett’s esophagus (BE) is a common condition that predisposes to cancer development. This article provides a current evidence-based review for controversial issues that impact the management of patients with BE, including clinical aspects, diagnosis, surveillance, and management of dysplasia and early cancer.